Cell Therapeutics' Unique Orally Available, Multi-Kinase (JAK2, FLT3, c-Fms) Inhibitor CT-1578 Demonstrates Ability to Prevent

 Cell Therapeutics' Unique Orally Available, Multi-Kinase (JAK2, FLT3, c-Fms)
  Inhibitor CT-1578 Demonstrates Ability to Prevent the Onset of Rheumatoid
 Arthritis and Potency in Treating and Reversing Bone and Cartilage Damage In
                              Preclinical Models

Results Reported in the Journal of Immunology

PR Newswire

SEATTLE, Oct. 15, 2012

SEATTLE, Oct. 15, 2012 /PRNewswire/ --Cell Therapeutics, Inc. ("CTI") (Nasdaq
and MTA: CTIC) announced today that CT-1578's (previously known as SB-1578)
unique kinase spectrum that selectively inhibits JAK2 over JAK1 or JAK3,
coupled with its inhibition of FLT-3 and c-Fms, produced potency in not only
preventing the development of rheumatoid arthritis ("RA"), but also in its
treatment and reversal of bone and joint destruction after the onset of RA in
preclinical models according to results published in the October 15, 2012
issue of the Journal of Immunology.

The authors concluded that CT-1578's selective inhibition of JAK2, FLT-3 and
c-Fms, which are the three kinases that are critical to the pathogenesis of
RA, is unprecedented in the current stable of kinase inhibitors.

"These results support the hypothesis that inhibition of JAK1 and JAK3 is not
mandatory for therapeutic benefit in RA," noted Jack W. Singer, M.D., EVP
Global Medical Affairs and Translational Medicine at CTI. "The results
demonstrate that CT-1578's unique kinase spectrum not only blocks the
inflammatory response, but prevents the infiltration of macrophages and
neutrophils into affected joints, while inhibiting antigen presenting
dendritic cells and the autoimmune component of the disease. These attributes
resulted in prevention of joint synovial hyperplasia and bone destruction,
that was sufficiently impressive that the Journal of Immunology chose to use
images of the results on the cover of the October 15^th issue."

About the Study

In the study, when SB1578 was orally administered in a preclinical model of
RA, it demonstrated a reduction of the level of proinflammatory cytokines,
which was accompanied by a reduction in joint inflammation. In RA patients,
the increase in cytokines correlates with disease progression and joint
destruction. In the preclinical model, SB1578 was also effective in reversing
an elevation in neutrophils, which play an essential role in the initiation of
joint inflammation and damage to bone and cartilage resulting in a mitigation
of damage to the joints. Additionally, SB1578 showed the ability to modulate
the autoimmune component of RA that is involved in the early development of RA
by inhibiting a pathway that leads to the initiation of an inflammatory
response. The authors state, "The activities against these three kinases
[JAK2, FLT-3 and c-Fms], which play crucial roles in the pathogenesis of
arthritis, differentiates SB1578 from other less selective JAK family kinase
inhibitors that are in clinical development for rheumatoid arthritis and
provides a novel and attractive therapeutic alternative."

The publication by Madan, et al. titled "SB1578, a Novel Inhibitor of JAK2,
FLT3, and c-Fms for the Treatment of Rheumatoid Arthritis," is available at
http://www.jimmunol.org/.

About Janus Associated Kinase (JAK)

The JAK family of enzymes are a central component in signal transduction
pathways, which are critical to normal blood cell growth and development as
well as inflammatory cytokine expression and immune responses. When
dysregulated by activating mutations, uncontrolled blood cell growth can occur
accompanied by inflammation and immune system activation contributing to
disease manifestations in myeloproliferative neoplasms. Autoimmune diseases
such as psoriasis and rheumatoid arthritis also have activation of this
pathway.

About FLT-3

FLT-3 is a tyrosine kinase that is important for RA pathogenesis as FLT-3
mediated signaling is essential in the differentiation of dendritic cells
leading to the to the amplification of systemic arthritogenic immune
responses. FLT-3 has also been shown to contribute to the bone erosion in
arthritic joints.

About c-Fms

c-Fms is a tyrosine kinase receptor that is increased in several diseases that
involve chronic activation of tissue macrophages, including RA. Elevate levels
of its ligand M-CSF are observed in the joints of RA patients, contributing to
the development of macrophages and osteoclasts, which are the mediators of
bone erosion. Inhibition of c-Fms has been shown to inhibit the progression
of arthritis in preclinical models indicating that it may play a pivotal role
in the pathogenesis of RA.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to
developing an integrated portfolio of oncology products aimed at making cancer
more treatable. For additional information, please visit
www.CellTherapeutics.com.

Sign up for email alerts and get RSS feeds at our Web site,
http://www.CellTherapeutics.com/investors_alert

This press release includes forward-looking statements that involve a number
of risks and uncertainties the outcome of which could materially and/or
adversely affect actual future results and the market price of CTI's
securities. Specifically, the risks and uncertainties that could affect the
development of CT-1578 include risks associated with preclinical and clinical
developments in the biopharmaceutical industry in general, and with CTI-1578
in particular, including, without limitation, the potential failure of CT-1578
to prove safe and effective for the treatment of patients with RA, either
alone or in combination regimens, as determined by the U.S. Food and Drug
Administration and/or the European Medicines Agency, that CT-1578 may not
satisfy a medical need not currently addressed with existing non-selective or
less selective JAK1/JAK2 inhibitors, that CT-1578 may not prevent the onset of
RA and/or treat or reverse bone and cartilage damage from RA, that additional
clinical trials of CT-1578 may not occur as planned, that the projected
benefits of the acquisition of CT-1578 may not materialize as expected, that
CTI may not be able to successfully implement its plans, strategies and
objectives related to the acquisition and development of CT-1578, CTI's
ability to continue to raise capital as needed to fund its operations,
competitive factors, technological developments, costs of developing,
producing and selling CTI's product candidates, and the risk factors listed or
described from time to time in CTI's filings with the Securities and Exchange
Commission including, without limitation, CTI's most recent filings on Forms
10-K, 10-Q and 8-K. Except as may be required by law, CTI does not intend to
update or alter its forward-looking statements whether as a result of new
information, future events, or otherwise.

Media Contact:

Dan Eramian
T: 206.272.4343
C: 206.854.1200
E: deramian@ctiseattle.com
www.CellTherapeutics.com/press_room

Investors Contact:

Ed Bell
T: 206.282.7100
E: invest@ctiseattle.com
www.CellTherapeutics.com/investors

Medical Information Contact:

T: 800.715.0944
E: info@askarm.com

SOURCE Cell Therapeutics, Inc.

Website: http://www.celltherapeutics.com
 
Press spacebar to pause and continue. Press esc to stop.